Who are Norcaine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ranexa, Naropin, Cerebyx, Decabid, ENCAINIDE, Tessalon.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/benzocaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Norcaine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Norcaine (BENZOCAINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Standardized Chemical Allergen [EPC]. Area: Metabolic.

marketed Standardized Chemical Allergen [EPC] Sodium channel protein type 5 subunit alpha Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Norcaine (BENZOCAINE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Norcaine TARGET	BENZOCAINE		marketed	Standardized Chemical Allergen [EPC]	Sodium channel protein type 5 subunit alpha
Ranexa	RANOLAZINE	Menarini Intl	marketed	Anti-anginal [EPC]	Sodium channel protein type 5 subunit alpha	2006-01-01
Naropin	ROPIVACAINE	Fresenius Kabi	marketed	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	1996-01-01
Cerebyx	FOSPHENYTOIN	Pfizer	marketed	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01
Decabid	INDECAINIDE	Eli Lilly	marketed		Sodium channel protein type 5 subunit alpha	1989-01-01
ENCAINIDE	ENCAINIDE		marketed	encainide	Sodium channel protein type 5 subunit alpha	1986-01-01
Tessalon	benzonatate	Generic (originally Pfizer)	marketed	Non-narcotic Antitussive [EPC]	Sodium channel protein type 5 subunit alpha	1958-01-01

Recent regulatory actions (last 90 days)

2026-03-30 — Tessalon · FDA · approved · US · Generic (originally Pfizer)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-01-24 — Ranexa · 11510878 · Formulation · US
2038-01-24 — Ranexa · 12161761 · Formulation · US
2038-01-24 — Ranexa · 10898444 · Formulation · US

Sponsor landscape (Standardized Chemical Allergen [EPC] class)

· 7 drugs in this class
Deseret Biologicals, Inc. · 2 drugs in this class
Donat R. Spahn · 1 drug in this class
Dr. Laurence Klotz · 1 drug in this class
Marjan Industria e Comercio ltda · 1 drug in this class
Millet Roux · 1 drug in this class
Nantes University Hospital · 1 drug in this class
Nutritional Specialties, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Tablicaps · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norcaine — Competitive Intelligence Brief. https://druglandscape.com/ci/benzocaine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing